Skip to main content
Cingulate Inc. logo

Cingulate Inc. — Investor Relations & Filings

Ticker · CING ISIN · US17248W1137 US Manufacturing
Filings indexed 445 across all filing types
Latest filing 2025-06-24 Director's Dealing
Country US United States of America
Listing US CING

About Cingulate Inc.

https://www.cingulate.com/

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The company utilizes its proprietary Precision Timed Release (PTR) drug delivery platform, a novel erosion-based technology, to create medications with a true once-daily dosing profile. This platform is designed to provide controlled drug release for entire active-day efficacy. Cingulate's pipeline includes product candidates CTX-1301 and CTX-1302 for the ADHD market, and CTX-2103 for the anxiety market.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-06-24 English
4
Director's Dealing
2025-06-24 English
8-K
Regulatory Filings
2025-06-11 English
8-K
Regulatory Filings
2025-05-13 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-08 English
8-K
Regulatory Filings
2025-05-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.